secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0001493152-22-012856
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte Q1 revenue $1.4M, net loss widens; CFO and Chairman transitions announced
--------------------------------------------------------------------------------

- Q1 2022 total revenue $1.4M vs $1.1M YoY; DetermaRx revenue $1.0M.
- Net loss $10.3M ($0.11 per share) vs net loss $3.9M ($0.05) a year ago.
- Cash, equivalents & marketable securities $22.7M as of March 31, 2022.
- Chairman Cavan Redmond not standing for reelection; Andrew Arno appointed Chairman effective May 6.
- CFO Mitchell Levine to transition to Corporate Development Officer; Anish John named Interim CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/0001493152-22-012856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-012856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer